Diabetes agents in the elderly: An update of new therapies and a review of established treatments

Clinical Geriatrics

Volumn 18, Issue 6, 2010, Pages 24-30

  Arzumanyan, Hasmik ^a   Kant, Ravi ^a   Thomas, Asha ^a,b  

^a SINAI HOSPITAL OF BALTIMORE   (United States)

^b Johns Hopkins/Sinai Hospital Program in Internal Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA;

ABDOMINAL CRAMP; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE PANCREATITIS; ADD ON THERAPY; ADJUVANT THERAPY; ANEMIA; ANOREXIA; DIABETIC PATIENT; DIARRHEA; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; FLATULENCE; FLUID RETENTION; FRACTURE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LACTIC ACIDOSIS; LOW DRUG DOSE; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PERIPHERAL EDEMA; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 77954626199     PISSN: 10951598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. American Community Survey. http://www.census.gov/acs/www/index.html. U.S. Census bureau. Accessed May 25, 2010.
2. Morrow lA, Halter Jb. Diabetes mellitus in the older adult. Geriatrics 1988;43(suppl):57-65.
3. Centers for Disease Control and Prevention. National diabetes fact sheet: General information and national estimates on diabetes in the United States, 2007. www.cdc.gov/Diabetes/pubs/pdf/ndfs-2007.pdf. Accessed May 10, 2010.
4. Koro CE, bowlin SJ, bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: A preliminary report. Diabetes Care 2004;27(1):17-20.
5. Amori RE, lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 2007;298(2):194-206.
6. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368(9548):1696-1705.
7. Doggrell SA. Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide. Rev Recent Clin Trials 2007;2(1):77-84.
8. Feinglos MN, Saad MF, Pi-Sunyer FX, et al. Effects of liraglutide (NN2211), a long-acting GlP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabet Med 2005;22(8):1016-1023.
9. Kim D, MacConell l, Zhuang D, et al. Effects of once-weekly dosing of a longacting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30(6):1487-1493. Published Online: March 12, 2007.
10. brunetti l, Orlando G, Recinella l, et al. Glucagon-like peptide 1 (7-36) amide (GlP-1) and exendin-4 stimulate serotonin release in rat hypothalamus. Peptides 2008;29(8):1377-1381. Published Online: April 20, 2008.
11. Pérez-Tilve D, González-Matias l, Alvarez-Crespo M, et al. Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes 2007;56(1):143-151.
12. Nelson P, Poon T, Guan X, et al. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther 2007;9(4):317-326.
13. buse Jb, Henry RR, Han J, et al; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27(11):2628-2635.
14. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5):1092-1100.
15. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28(5):1083-1091.
16. Heine RJ, Van Gaal lF, Johns D, et al; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 2005;143(8):559-569.
17. Madsbad S, Schmitz O, Ranstam J, et al; NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27(6):1335-1342.
18. byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2009. http://pi.lilly.com/us/byetta-pi.pdf. Accessed May 10, 2010.
19. Charbonnel b, Karasik A, liu J, et al; Sitagliptin Study Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29(12):2638-2643.
20. Aschner P, Kipnes MS, lunceford JK, et al; Sitagliptin Study Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29(12):2632-2637.
21. Januvia [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2010. http://www.merck.com/product/usa/pi-circulars/j/januvia/januvia-pi. pdf. Accessed May 10, 2010.
22. Koda JE, Fineman M, Rink TJ, et al. Amylin concentrations and glucose control. Lancet 1992;339(8802):1179-1180.
23. Ryan GJ, Jobe lJ, Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 2005;27(10):1500-1512.
24. Sexton PM, Paxinos G, Kenney MA, et al. In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 1994;62(2):553-567.
25. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control. Curr Pharm Des 2001;7(14):1353-1373.
26. Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002;25(4):724-730.
27. Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: A 1-year, randomized controlled trial. Diabet Med 2004;21(11):1204-1212.
28. Hollander PA, levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care. 2003;26(3):784-790.
29. Thompson RG, Pearson l, Kolterman OG. Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: Effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia 1997;40(11):1278-1285.
30. Weyer C, Fineman MS, Strobel S, et al. Properties of pramlintide and insulin upon mixing. Am J Health Syst Pharm 2005;62(8):816-822.
31. Symlin [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2005. http://www.amylin.com/products/symlin.htm.
32. Hoogwerf bJ, Doshi Kb, Diab D. Pramlintide, the synthetic analogue of amylin: Physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc Health Risk Manag 2008;4(2):355-362.
33. bolen S, Feldman l, Vassy J, et al. Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus [published correction appears in Ann Intern Med 2007;147(12):887]. Ann Intern Med 2007;147(6):386-399.
34. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet 1999;354(9178):602]. Lancet 1998;352(9131):837-853.
35. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. JAMA 2002;287:360-372.
36. Nathan DM. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002;347:1342-1349.
37. brown AF, Mangione CM, Saliba D, Sarkisian CA; California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003;51(5 suppl guidelines):S265-S280.
38. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group [published correction appears in BMJ 1999;318(7175):29]. BMJ 1998;317(7160):703-713.
39. Haffner SM, lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339(4):229-234.
40. Wolff Jl, Starfield b. Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002;162(20):2269-2276.
41. Alexander GC, Sehgal Nl, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168(19):2088-2094.